Nuvalent (NUVL) CFO sells 1,683 shares at $85.57 avg; Form 4

Nuvalent (NUVL) reported an insider transaction by its Chief Financial Officer.

Rhea-AI Filing Summary

Nuvalent (NUVL) reported an insider transaction by its Chief Financial Officer. On 10/15/2025, the CFO exercised 1,683 stock options at $18.93 per share and sold 1,683 Class A shares at a weighted average price of $85.57, with individual sales ranging from $85.00 to $85.69. The trades were made under a Rule 10b5-1 plan adopted on December 12, 2024.

Following these transactions, the CFO beneficially owned 61,734 Class A shares directly and 28,979 derivative securities (stock options). The filing lists transaction codes M (option exercise) and S (sale).

Insider Trade Summary

Exercise and Sale: 1,683 shares ($112K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Balcom Alexandra

Role Chief Financial Officer

Sold 1,683 shs ($144K)

Approx. gross sale proceeds $144K

Approx. exercise cost $32K

Approx. pre-tax spread $112K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	1,683	$0.00	$0.00
Exercise	Class A Common Stock	1,683	$18.93	$32K
Sale	Class A Common Stock	1,683	$85.57	$144K

Holdings After Transaction: Stock Option (Right to Buy) — 28,979 contracts (Direct); Class A Common Stock — 61,734 shares (Direct)

Footnotes (3)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.69, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price.
3. F3. The shares underlying this option vest as follows: 25% of the shares vested on January 4, 2023, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nuvalent (NUVL) disclose in this Form 4?

The CFO exercised 1,683 stock options at $18.93 and sold 1,683 shares at a weighted average price of $85.57 on 10/15/2025.

Were the NUVL trades made under a Rule 10b5-1 plan?

Yes. The transactions were effected under a Rule 10b5-1 trading plan adopted on December 12, 2024.

What price range were the NUVL shares sold at?

Sales occurred in multiple trades at prices ranging from $85.00 to $85.69, inclusive.

How many NUVL shares does the CFO own after the transactions?

The CFO beneficially owned 61,734 Class A shares directly after the reported transactions.

How many stock options remain after the transactions?

The filing shows 28,979 derivative securities (stock options) beneficially owned following the transactions.

What do the transaction codes M and S indicate?

M denotes an option exercise; S denotes an open market sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/17/2025 - 04:31 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Balcom Alexandra

(Last) (First) (Middle)

C/O NUVALENT, INC.

ONE BROADWAY, 14TH FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvalent, Inc. [ NUVL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	10/15/2025		M(1)		1,683	A	$18.93	63,417	D
Class A Common Stock	10/15/2025		S(1)		1,683	D	$85.57(2)	61,734	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18.93	10/15/2025		M(1)			1,683	(3)	01/04/2032	Class A Common Stock	1,683	$0.00	28,979	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.69, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price.

3. The shares underlying this option vest as follows: 25% of the shares vested on January 4, 2023, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

	/s/ Nathan N. McConarty, attorney-in-fact	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.